The Mesoblast Limited (ASX: MSB) share price has been a strong performer on Tuesday.
In morning trade the leading allogeneic cellular medicines developer’s shares are up 4% to $1.98.
Why is the Mesoblast share price charging higher?
Investors have been buying Mesoblast’s shares this morning following the release of an update on the phase 3 trial of Revascor for advanced chronic heart failure.
According to the release, Mesoblast has surpassed the number of primary endpoint events required for trial completion.
The cardiovascular outcomes trial has now initiated its final study visits for all surviving patients. It is aiming to complete the last patient visit at the end of January 2020.
After which, final data collection and entry processes will be performed and the database locked. All surviving patients will have been followed for at least 12 months, with a mean follow up period of approximately 30 months.
The results from this pivotal trial are expected to be available by mid-2020.
What is the trial?
The trial in question is a double-blind, randomised, sham procedure-controlled Phase 3 trial.
It is evaluating Revascor as an add-on treatment to standard-of-care for reduction of recurrent non-fatal heart failure-related major adverse cardiac events (HF-MACE) and terminal cardiac events (TCEs) in 566 patients with advanced chronic heart failure and reduced ejection fraction.
In the United States there are more than 6.5 million patients with heart failure. Approximately 15% of this patient population has advanced chronic heart failure and is at high-risk for recurrent HFMACE and TCEs. This high-risk group makes up the predominant patient population in the Revascor Phase 3 trial.
Mesoblast’s chief executive, Dr Silviu Itescu, was very pleased with the news.
He said: “We are very pleased to have achieved this important milestone in the largest trial of cell-based therapy for patients with advanced heart failure. These patients have exhausted other treatment alternatives, and have the highest burden of disease, recurrent hospitalizations and mortality.”
Our Motley Fool experts have just released a brand new FREE report, detailing 5 dirt cheap shares that you can buy today.
One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…
Another is a diversified conglomerate trading near a 52-week low all while offering a 2.8% fully franked yield...
Plus 3 more cheap bets that could position you to profit over the next 12 months!
See for yourself now. Simply click the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.